Vitiligo is often viewed as a cosmetic condition because of the white patches it causes on the skin. But scientists and dermatologists increasingly emphasise that the disorder goes far beyond appearance. Growing evidence shows that vitiligo is an immune-mediated disease in which the body's own immune system mistakenly attacks melanocytes, the cells responsible for producing skin pigment. Researchers are also finding that people with vitiligo have a higher likelihood of developing other autoimmune conditions, highlighting that the disease reflects broader immune dysfunction rather than a purely cosmetic concern.
According to a 2024 systematic review and meta-analysis involving 171 studies and more than 572 million participants, the overall global prevalence of vitiligo was estimated at 0.40 per cent, with adults being more commonly affected than children. The researchers also noted that the condition may be under-recognised because it is often viewed as a cosmetic issue rather than an autoimmune disease.
Adding to this evidence, a 2026 review described vitiligo as a prototypical CD8+ T cell-mediated autoimmune disease and highlighted how advances in understanding its immune mechanisms have led to the development of the first FDA-approved immune-modulating treatments.
On the occasion of World Vitiligo Day, we spoke to Dr Priyanka Kuri, Consultant - Dermatology at Aster Whitefield Hospital to understand why vitiligo is considered an autoimmune disease, how the immune system drives the loss of pigmentation, and why recognising its underlying biology is important for treatment and long-term care.
Vitiligo is more than a cosmetic concern
Dr Priyanka Kuri said vitiligo has long been viewed primarily through a cosmetic lens because of the visible white patches it causes. However, growing evidence suggests that it is a chronic autoimmune disease that deserves the same clinical attention as other immune-mediated conditions.
"Vitiligo is not just a problem of appearance. It is an autoimmune disorder in which the body's immune system mistakenly attacks melanocytes, the cells responsible for producing pigment. Recognising its autoimmune nature is important because it allows us to provide comprehensive care rather than focusing only on skin colour changes," she said.
According to Dr Kuri, research over the past two decades has shown that genetic susceptibility, immune dysfunction and environmental triggers all contribute to the disease. Cytotoxic T-cells play a central role in destroying melanocytes, leading to the characteristic depigmented patches.
Vitiligo often coexists with other autoimmune disorders
Dr Kuri noted that one of the strongest arguments for recognising vitiligo as an autoimmune condition is its association with several other immune-mediated diseases.
"People with vitiligo have a higher likelihood of developing autoimmune thyroid diseases such as Hashimoto's thyroiditis and Graves' disease. Other associated conditions include type 1 diabetes, alopecia areata, pernicious anaemia and certain connective tissue disorders," she said.
Because of these links, dermatologists may recommend appropriate screening when symptoms or family history suggest an increased risk. She added that this broader approach shifts the focus from appearance alone to overall health and long-term monitoring.
Calling vitiligo 'just cosmetic' can delay care
Dr Kuri said describing vitiligo as merely a cosmetic condition can underestimate both its physical and psychological impact. Many patients experience anxiety, depression, social withdrawal and loss of confidence, particularly when the patches affect visible areas such as the face, hands and scalp.
"When people believe that vitiligo is only a cosmetic issue, they may postpone seeking medical attention because the condition is not physically painful. But recognising it as an autoimmune disease validates patients' experiences and highlights the importance of medical treatment alongside emotional and psychological support," she said.
New treatments reflect a better understanding of the disease
According to Dr Kuri, advances in the understanding of vitiligo have transformed treatment strategies. While conventional therapies such as topical medications and phototherapy remain important, newer treatments increasingly target the immune pathways responsible for melanocyte destruction.
"The development of targeted therapies, including Janus kinase (JAK) inhibitors, represents a major shift in the management of vitiligo. Instead of only trying to restore pigment, these therapies aim to address the underlying immune mechanisms driving the disease," she said.
Dr Kuri emphasised that early diagnosis and intervention can help limit ongoing damage to melanocytes and potentially improve outcomes. She added that increasing public awareness and moving beyond the perception of vitiligo as a cosmetic concern could reduce stigma, improve access to treatment and ensure patients receive the holistic care they need.
This story is done in collaboration with First Check, which is the health journalism vertical of DataLEADS
